Back to top
more

Tandem Diabetes Care (TNDM)

(Delayed Data from NSDQ)

$43.97 USD

43.97
735,574

+0.74 (1.71%)

Updated Jul 23, 2024 04:00 PM ET

After-Market: $43.97 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth B Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for TNDM

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Tandem Diabetes Care, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 468 617 624 485 176
Receivables 106 115 111 82 47
Notes Receivable 0 0 0 0 0
Inventories 158 111 69 64 49
Other Current Assets 17 7 8 6 4
Total Current Assets 748 850 812 637 276
Net Property & Equipment 77 69 50 50 33
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 40 24 16 9 1
Total Assets 953 1,053 905 716 326
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 50 56 28 18 18
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 56 48 61 39 36
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 72 48 34 38 39
Total Current Liabilities 195 165 132 104 99
Mortgages 0 0 0 0 0
Deferred Taxes/Income 13 17 0 0 0
Convertible Debt 285 283 281 203 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 32 24 35 27 18
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 639 613 472 350 131
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 1,264 1,171 1,068 1,025 820
Retained Earnings -952 -729 -635 -659 -625
Other Equity 1 -2 -1 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 314 440 433 366 195
Total Liabilities & Shareholder's Equity 953 1,053 905 716 326
Total Common Equity 314 440 433 366 195
Shares Outstanding 65.20 64.30 63.50 60.90 59.00
Book Value Per Share 4.81 6.84 6.82 6.01 3.30

Fiscal Year End for Tandem Diabetes Care, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 468 468 498 507
Receivables NA 93 106 100 99
Notes Receivable NA 0 0 0 0
Inventories NA 154 158 143 148
Other Current Assets NA 21 17 16 11
Total Current Assets NA 735 748 758 764
Net Property & Equipment NA 78 77 76 74
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 40 40 17 18
Total Assets NA 941 953 940 947
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 48 50 46 57
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 53 56 58 49
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 75 72 66 51
Total Current Liabilities NA 193 195 187 175
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 12 13 14 15
Convertible Debt NA 348 285 285 284
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 32 24 25
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 698 639 626 617
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 1,238 1,264 1,238 1,219
Retained Earnings NA -995 -952 -922 -889
Other Equity NA -1 1 -2 -1
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 243 314 314 329
Total Liabilities & Shareholder's Equity NA 941 953 940 947
Total Common Equity 0 243 314 314 329
Shares Outstanding 64.50 64.50 65.20 65.20 65.00
Book Value Per Share 0.00 3.77 4.81 4.82 5.07